RT @Aiims1742: Terrific preprint by @hartjackson using imaging mass cytometry (IMC) & matched genomics for building multimodality predictio….

RT @UofTSurgery: The @UofTSurgery community mourns the loss of cherished colleague, Dr. Sean Cleary. "Sean has touched the lives of many of….

What do you want to know?.

RT @CHPBAsurg: It is with deep sadness that the we mourn the sudden loss of our co-founder, past-president, mentor, colleague and friend Dr….

RT @FordePatrick: Another negative (or a few have been weakly positive) adjuvant only anti-PD-(L)1 phase 3 solid tumour trial. Neoadjuvan….

RT @TumorBoardTues: #TumorBoardTuesday. 😮We had a rare #ASCO25 with several key🗝️updates in #PancreaticCancer.So to put this in context:.📢J….

A huge 🇨🇦 team effort inc surgeons, scientists, pathologists, research staff, nurses, radiologists, bioinformaticians, oncologists, trainees.🌟collaboration, teamwork &mutual respect.🌟it takes a village @OICR_news @pmcancercentre @PanCancerCanada @cancersociety @UCDMedicine.

Final COMPASS trial data advanced #PDAC.➡️268 WGS& 253RNA-seq.➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets.➡️LTS :HRD, KRAS WT.➡️KRAS major enriches basal, >type II DM.➡️LAPC≠intact SMAD4.➡️47% receive 2nd line tx.

RT @ferguskeane2: Congrats to oncology trainee Mary O’Reilly presenting data from her PhD on early onset colorectal cancer at ESMO GI 2025….

RT @AASLDtweets: 🔥Hot Topic in @LTxJournal!. An international consensus conference was convened by the @_ILTS_ and the @ILCAnews to establi….

Tomorrow! the role of immunotherapy in the neoadjuvant setting is growing++.✅#SITC summit on future of clinical trial design #endpoints.✅advances, opportunities & challenges .🔥Promises to be a superb &engaging summit @sitcancer @FordePatrick 👇.@CancerInstIRE @UCDCancerTrials.

RT @AAFretland: “Transplant oncology is chasing the highest tumor load associated with cure” .Great update from Vincenzo Mazzaferro, includ….

RT @AAFretland: Breaking news! Pump vs transplant is no longer a debate❤️. The parties (dr. Kingham and dr. Chapman) have come to agreement….

Optimal approach in BR-PDAC/LAPC.✅starting with neoadjuvant therapy.❓is there a role for switch tx ?PAXG?.❓how do we incorporate CA19.9 dynamics.❓ what’s the best biomarker .Fantastic talk from @BasGrootKoerkam .#PDAC #EAHPBA2025

RT @OncoAlert: Dear Colleagues.Thank you for Another amazing day at our Annual #OncoAlert5k 🏃‍♀️at #ASCO25 , we look forward to seeing you….

RT @MGMcNamara: Professional presentation by @RonanAndrewMcL1 also highlighting N.B. Adequate tissue for analysis: 98% research biopsies en….

🔥NeoPancOne🇨🇦.➡️mFFX in resectable PDAC .➡️exploring GATA6&subtypes .➡️mEFS &OS 16.3 &34.2mths.➡️1yr EFS 90% in GATA6 hi vs 50% lo.➡️1yr OS classical 95% vs.57% basal-like.⭐️Time to subtype upfront in all PDAC recognising plasticity @OncoAlert #ASCO25 @OICR_news @pmcancercentre

TEDOPAM - maintenance randomised phase 2 vaccine trial #PDAC .Induction mFFX- Folfiri vs Folfiri+ OSE2101 (TAAs).➡️106 pts .➡️met primary endpoint of 12mth OS>50%; .➡️But control arm mOS 17 vs vaccine arm 15mths.➡️highlights benefit maintenance approaches @ASCO @OncoAlert #ASCO25

🔥POLCAGB Ph 3 neoadjuvant chemo vs neoadjuvant chemorads + chemo in locally adv GBC.➡️ closed at interim due to poor accrual.124 pts randomised.➡️ORR 74% vs 36%.➡️mOS 22mths vs 10ths.Imp data - rads has a role!.Nb 20% her2 amp in GBC- needs explored.#ASCO25 @ASCO @OncoAlert

GnP vs GnP+elraglusib in advanced #PDAC.➡️2:1 randomisation .➡️interesting inhibitor of GSK-3beta.➡️mOS 10.1 vs 7.2 mths .GNP arm did poorly and still mOS <1 yr.#ASCO25 @asco @OncoAlert

PANOVA-03 LAPC GnP vs GnP + TTFields #ASCO25 @ASCO @OncoAlert .➡️571 patients randomised.➡️mOS 16.2 mths vs 14.2mths.➡️pain free survival longer .➡️mainly skin reactions for TTFields